SURPASS-6 compared two add-on approaches for people already receiving basal insulin. Its hypoglycemia result illustrates why the unit beside a number cannot be omitted. Primary report
Study snapshot
This open-label trial randomized 1,428 participants to tirzepatide or prandial insulin lispro added to glargine. At 52 weeks, the pooled tirzepatide comparison favored HbA1c and weight reduction. The reported clinically significant or severe hypoglycemia rates were 0.4 versus 4.4 events per patient-year. Gastrointestinal adverse events occurred with tirzepatide. The abstract reports 1,304 trial completers. Primary report
Our appraisal: count events and people separately
An event rate permits repeated events in the same person. It is not interchangeable with the proportion of participants who experienced at least one event. Rewriting events per patient-year as a percentage affected produces a different and unsupported claim.
A hypothetical example makes the distinction concrete: ten events could occur in ten people once each, or in one person ten times. Those patterns have the same event count but very different distributions across people. Neither pattern is being asserted for this trial.
The pooled treatment estimate also needs its label. A result combining several assigned treatment groups should not be presented as though it came from a single fixed regimen. Full release review should reconcile participant flow, inspect exposure time and recurrent-event methods, and compare discontinuations and gastrointestinal outcomes alongside glucose and weight.
This report evaluates an add-on strategy. It does not support a consumer protocol for combining research materials with prescribed insulin.
Frequently asked questions
Was lispro the basal insulin?
No. It was the prandial comparator added to background glargine.
Does 0.4 events per patient-year mean 0.4% of people?
No. Those are different measures.
Can one person contribute several events?
Yes, which is why event counts need careful interpretation.
Was the primary tirzepatide estimate pooled?
Yes. The comparison combined tirzepatide groups.
Was there no gastrointestinal burden?
No. Gastrointestinal adverse events were reported.
Is this a self-administration guide?
No. It is a study-interpretation page.
What remains unresolved before release?
Full participant flow, safety detail, and complete analysis methods require review.